Mylan Completes Acquisition of Jai PharmaBy
Mylan N.V.’s subsidiary, Mylan Laboratories Limited, has successfully completed the acquisition of certain women’s healthcare businesses, now known as Jai Pharma, which were spun off from Famy Care Limited. The transaction brings Mylan a broad women’s care portfolio, strong technical capabilities, and dedicated hormone manufacturing.
Mylan CEO Heather Bresch commented in a company statement: “The completion of this transaction is an important milestone as we continue to grow our global women’s healthcare franchise, and take another step in our mission to provide the world’s 7 billion people access to high quality medicine. In addition to strengthening our women’s healthcare offering in North America, we will continue to leverage our powerful commercial platform in Europe, now enhanced through our recent Abbott deal, to serve this important therapeutic area.
Moreover, we look forward to building upon our existing commercial presence in emerging markets by leveraging our global supply chain and operational excellence to further accelerate our growth. This will include building upon our existing women’s care portfolio in India and expanding our reach in support of Family Planning 2020, a global partnership that aims to enable 120 million more women and girls to use contraceptives by 2020.